Abstract 4765
Background
Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for R/M HNSCC but only a minority benefits. c-Met and EGFR signaling converge at the PI3K/Akt and MAPK nodes. Preclinical evidence shows that c-Met can drive tumor-intrinsic resistance to EGFR inhibition. Ficlatuzumab is an IgG1 mAb against HGF, the sole ligand for cMet. We recently completed a phase Ib study evaluating ficlatuzumab and cetuximab in pts with cetuximab-resistant, R/M HNSCC (Bauman JE et al, ASCO 2017). Twelve pts were treated; 11 were platinum-refractory. Grade 3 adverse events included edema, hypoalbuminemia, infection, and thromboembolism. No DLTs were seen. Median progression-free survival (PFS) at the recommended phase II dose (RP2D) was 6.0 mos (90% CI = 2 mos – not reached). Confirmed overall response rate (ORR) was 17% (90% CI = 0-28%). Clinical benefit rate was 67%. Serum Veristrat, a proteomic classifier predictive of differential treatment benefit from anti-EGFR therapy, did not correlate with PFS. We designed a randomized phase II trial evaluating ficlatuzumab with or without cetuximab in patients with cetuximab-resistant, R/M HNSCC. The combination arm follows the hypothesis that continued anti-EGFR blockade may overcome reciprocal compensation between the EGFR and cMet pathways.
Trial design
This is a multicenter phase II trial with a randomized, non-comparative, 2-arm design (Arm A: ficlatuzumab and Arm B: ficlatuzumab + cetuximab) in pts with R/M HNSCC after failure of cetuximab. Key eligibility criteria include: R/M HNSCC; cetuximab resistance (recurrence during or within 6 mos of cetuximab-radiation or palliative cetuximab); ECOG 0-1; mandatory baseline research biopsy. The primary objective is to assess the efficacy of ficlatuzumab, with or without cetuximab, as measured by PFS. To test the hypothesis that either regimen improves historical PFS from 2 months to 3.33 months requires 66 eligible patients. Key secondary endpoints are ORR and survival. Biomarkers to be correlated with efficacy include tumor HGF/cMet dimers, phosphoproteins, and immunoscores and serum Veristrat. Two of 66 patients have enrolled.
Clinical trial identification
Legal entity responsible for the study
University of Arizona Cancer Center.
Funding
University of Arizona Cancer Center; Aveo.
Editorial Acknowledgement
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract